KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2025)

Vir Biotechnology's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.3 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 60.53% year-over-year to -$0.3; the TTM value through Dec 2025 reached -$3.16, up 17.49%, while the annual FY2025 figure was -$3.16, 17.49% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.3 at Vir Biotechnology, up from -$1.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.94 in Q4 2021 and bottomed at -$1.57 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.78 (2024), against an average of -$0.19.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 552.87% in 2021 before it tumbled 226.09% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.94 in 2021, then crashed by 119.04% to -$0.75 in 2022, then dropped by 14.67% to -$0.86 in 2023, then rose by 11.63% to -$0.76 in 2024, then soared by 60.53% to -$0.3 in 2025.
  • Per Business Quant, the three most recent readings for VIR's EPS (Weighted Average and Diluted) are -$0.3 (Q4 2025), -$1.18 (Q3 2025), and -$0.8 (Q2 2025).